Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease
About This Grant
Despite extensive research, the mechanisms through which Aβ aggregates contribute to cellular and tissue dysfunction in Alzheimer’s Disease (AD) are still debated. This debate, centered on mechanisms of toxicity, also extends to other human amyloidoses. Though most efforts have focused on identifying toxic species or conformers (e.g., oligomers, protofibrils, fibrillar conformers) and the effects of these Aβ only assemblies, our latest findings propose an alternative, non-mutually exclusive hypothesis. Based on comprehensive proteomic analyses of human AD and control brains, along with mouse models of amyloid deposition, we have proposed the Amyloid Scaffold Hypothesis (ASH). This hypothesis suggests that the accumulation of numerous proteins, scaffolded by, and dependent on amyloid formation, represents a critical mechanism driving downstream pathophysiology in AD. Unlike traditional views of amyloid assembles as direct toxins, the ASH posits that amyloid-associated protein accumulation underpins disease progression. To explore this hypothesis, we will i) determine the molar abundance of proteins co-accumulating with Aβ in AD and Aβ-depositing mouse model brains and assess whether this correlates with changes in protein solubility ii) investigate the interactions driving protein co-accumulation with amyloid deposits, focusing on Aβ, amyloid, and heparan sulfate proteoglycans and iii) test whether extracellular accumulation of these co-aggregating proteins, in the absence of amyloid, induces downstream pathophysiologic changes like those seen in AD. These studies are highly significant. They will directly test a novel mechanism by which amyloid may mediate pathophysiologic effects and may provide clues as to normal physiologic associations of Aβ. Though focused on AD, this work could also have implications for other amyloidoses. This work integrates data and tools from AMP-AD, TREAT-AD, and MODEL-AD initiatives, and is supported by rigorous findings from published and unpublished studies.
Grant Summary
Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease is a NIA - National Institute on Aging grant providing up to $657K for university, nonprofit, healthcare org. Applications are due 2031-01-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $657K
2031-01-31
- 1Confirm your organization is eligible for Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease from NIA - National Institute on Aging, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIA - National Institute on Aging before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIA - National Institute on Aging's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease: Frequently Asked Questions
Who is eligible for the Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease?
Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease is offered by NIA - National Institute on Aging and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease provide?
Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease provides up to $657K per award from NIA - National Institute on Aging. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease deadline?
Applications for Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease are due 2031-01-31 (open). Because deadlines can change, verify the date with the funder, NIA - National Institute on Aging, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease?
To apply for Defining Pathological Roles of Novel Protein Interactions with Amyloid in Alzheimer's Disease, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIA - National Institute on Aging.